Brian Hodous is a co-founder of Recludix Pharma and serves as Senior Vice President of Chemistry. Dr. Hodous has nearly 20 years of experience in drug discovery and preclinical development. He spent his career at several large and start-up biotechnology companies, where he contributed to the discovery of multiple clinical molecules and one approved drug, set company strategy and implemented initiatives to foster team/culture building. Dr. Hodous was most recently the Head of Chemistry at Accent Therapeutics responsible for drug discovery strategy and chemical matter identification/optimization in the emerging area of RNA-modifying protein biology. From 2011 to 2017, Dr. Hodous was at Blueprint Medicines where he co-led the advancement of their proprietary kinase inhibitor library strategy and design efforts. During his tenure at Blueprint, he was a co-inventor and co-program lead for: AYVAKIT (avapritinib), a potent, selective KIT/PDGFR inhibitor approved for the treatment of patients with PDGFRa mutant GIST and patients with advanced systemic mastocytosis; Fisogatinib, a potent, selective, covalent inhibitor of FGFR4 in clinical trials for patients with hepatocellular carcinoma; and IPN60130 (out-licensed to Ipsen Biopharmaceuticals, formerly BLU-782), a potent, selective inhibitor of ALK2 kinase that is currently in Phase 2 clinical trials for the treatment of patients with the rare genetic disease, fibrodysplasia ossificans progressiva. While at EMD Serono, he co-invented and co-led the development of evobrutinib, a highly potent, selective, covalent BTK inhibitor that is currently in Phase 3 clinical trials for multiple sclerosis. From 2002-2008, Dr. Hodous was at Amgen where he co-invented AMG-900, a pan-Aurora kinase inhibitor that went into Phase 1 clinical trials for oncology indications. Dr. Hodous holds a Ph.D. in Organic Chemistry from MIT.
« Go Back